A Phase 2 interventional study of Lidocaine 5% medicated plaster and Placebo topical plaster in Pain, Chronic Pain and Neuropathic Pain, sponsored by Grünenthal GmbH. Terminated at 22 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-10-16.
Sponsored by Grünenthal GmbH · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 204 studies testing lidocaine in Pain — 19 open to participants now, 19 under way, 1 of them phase 3. Lidocaine · Pain.
Among the 204 studies testing lidocaine in Pain, this one is the 93rd largest by enrollment of the 203 interventional ones that give a count, is one of 17 that started in 2010, is one of 17 in phase 2, and was the 44th registered.
10,069 studies on the registry are indexed under Pain; 1,650 are open to participants now.
Browse Pain studies →19 of the 204 studies testing lidocaine in Pain are open now, in 9 countries. Recruiting first, the newest first:
Vanderbilt University Medical Center · Sites in United States
Ages 18+
Northwell Health · Sites in United States
Ages 18+ · Women only
Montefiore Medical Center · Sites in United States
Ages 18–50 · Women only
Cairo University · Sites in Egypt
Ages 18–65 · Healthy volunteers
Ain Shams University · Sites in Egypt
Ages 18–40 · Women only
By country, each count listing its studies:
Lidocaine: first FDA approval 1948 (XYLOCAINE), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →
Of the 927 Pain studies recruiting now, 382 (41%) set no upper age limit and 434 (47%) stop at 75 or younger; 146 take children under 18; 221 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
204 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 11 · Phase 2 32 · Phase 3 34 · Phase 4 63
First in 2002; this study’s year is marked. 17 started in 2010.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 74 is above the median of 66 across 8,505 interventional studies indexed under Pain.
Median enrollment 66 across the 203 interventional studies. Of the 157 that completed or were terminated, 66 (42%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 204 have an industry lead sponsor. The 10 most frequent:
Grünenthal GmbH is the lead sponsor of 69 studies on the registry; 3 are open to participants now.
Of its 13 completed or terminated interventional studies of FDA-regulated products, 8 (62%) have results posted.
19 studies in Pain by Grünenthal GmbH: 1 open now, 1 under way, none of them phase 3. Of 18 finished, 11 (61%) have results posted.
Among the 19 studies in Pain by Grünenthal GmbH, this one is the 12th largest by enrollment, is the only one that started in 2010, is one of 3 in phase 2, and was the 9th registered.
Grünenthal GmbH’s Pain studies by the year they started, since 2003.
5 of the studies testing lidocaine in Pain that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07785674Mayo ClinicArm Elevation for Prevention of Propofol Injection Pain | 2027-01 |
| NCT07883473Shaheed Zulfiqar Ali Bhutto Medical UniversityPudendal Nerve Block for Pain Relief During Episiotomy Repair | 2027-01-31 |
| NCT07889687Northwell HealthThis Study is Comparing Pain Outcomes After Urethral Bulking When Participants Are Randomized to Two Different Pain Medication Regimens. | 2027-04 |
| NCT07546370Monakshi SawhneyThe Effectiveness of Topical Prilocaine-Lidocaine Cream Plus Acetaminophen and Naproxen Compared to Lidocaine Injection Plus Acetaminophen and Naproxen to Manage Pain During IntraUterine Device Insertion | 2027-04-14 |
| NCT07048769Montefiore Medical CenterParacervical Block for Pain Reduction in Saline Infusion Sonograms | 2027-07 |
Add all 5 to your calendar (.ics) → With an account.
Among the 204 studies testing lidocaine in Pain, from their registry updates:
Among Grünenthal GmbH’s 19 in Pain:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this trial is to investigate the efficacy and safety of lidocaine 5% medicated plaster in localized chronic post-operative neuropathic pain in comparison to placebo plaster.
Some patients who undergo different types of surgery develop distressing and long-lasting pain. This pain is often characterized by signs such as: allodynia (a pain due to a stimulus which does not normally provoke pain), dysesthesia (unpleasant, abnormal sense of touch). Patients describe symptoms of burning or electrical type sensation. In some cases this type of chronic pain can still be present after 3 months or more following surgery.This clinical trial will assess the efficacy and safety profile of lidocaine 5% medicated plaster in comparison to placebo plaster in patients.
This trial is a randomized, double-blind (neither investigator nor patient will know which treatment was received), placebo-controlled, parallel-group, multicenter trial to evaluate topical analgesic treatment of chronic neuropathic pain after surgery. The trial will include a screening phase and a treatment phase, during which subjects will be treated with either 5% lidocaine medicated plaster, or a placebo plaster pain intensity will be assessed on a daily basis. Subsequently there will be a follow-up phase. Pain intensity numeric rating scale (PI) will be collected via the numeric rating scale and averaged. Safety evaluations include monitoring of adverse events, physical examinations, and clinical laboratory tests.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Active Comparator
Drug: Placebo topical plaster
Drug: Lidocaine 5% medicated plaster
Topical hydrogel plaster (700mg lidocaine)
Also known as: Versatis(R)
Topical hydrogel plaster
Analgesic efficacy of lidocaine 5% medicated plaster in comparison to placebo in subjects with moderate to severe localized chronic postoperative neuropathic pain
Participants will be selected based on their medical history and clinical examination. A questionnaire called DN4, which stands for 'douleur neuropathique 4' (i.e., '4 questions neuropathic pain will be used to identify subjects with neuropathic pain.) Pain will be assessed on and 11-point numerical rating scale (0 = no pain, 10 = worst pain imaginable). Efficacy of the treatment (i.e., reduction of neuropathic pain) will be evaluated with the 11-point numeric rating scale (NRS).
Time frame: daily assessments over 4 weeks
Effect of lidocaine 5% medicated plaster on quality of life
EuroQol-5 Dimension Scores
Time frame: 4 weeks
Neuropathic Pain Symptoms
Changes in severity of various neuropathic pain symptoms, e.g. allodynia, will be recorded by the Neuropathic Pain Symptom Inventory (NPSI) and neurological examinations
Time frame: 4 weeks
Incidence of adverse events
Measurement of adverse events including those derived from laboratory data or vital signs measurements.
Time frame: up to 44 days
Hospital Anxiety and Depression Scale
Time frame: 4 weeks
Subject's Global Impression of Change
Time frame: 4 weeks
Treatment Satisfaction Questionnaire for Medication
Time frame: 4 weeks
The record gives a start of Aug 2010, a primary completion of Nov 2012 and a completion of Nov 2012. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Oct 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Lidocaine